Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 2;17(9):1163.
doi: 10.3390/ph17091163.

Drug Delivery Systems for Glaucoma: A Narrative Review

Affiliations
Review

Drug Delivery Systems for Glaucoma: A Narrative Review

Antonio M Fea et al. Pharmaceuticals (Basel). .

Abstract

Glaucoma is one of the world's leading causes of blindness, and its management is challenging. The main objective is to lower intraocular pressure through medical, para-surgical, and surgical therapy. Medical therapy often represents the first line of treatment. Although effective in many cases, the eye drops are accompanied by significant problems. They require high patient compliance and can be associated with various side effects, limiting their efficacy. Consequently, the research for new drug delivery systems trying to overcome these limitations is ongoing: numerous devices are developing and gradually entering clinical practice. These new therapeutic options may offer better control of the intraocular pressure, with fewer side effects, and are less dependent on patients' compliance. Hence, the research in this field continues to flourish. This review summarizes the most recent findings in the scientific literature, underlines the role and possible limitations of the new glaucoma drug delivery systems in clinical practice, and recognizes their new horizons and perspectives.

Keywords: conjunctival fornix delivery systems; drug-laden contact lenses; glaucoma; intracameral delivery systems; periocular drug delivery systems; punctal plug delivery systems.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Punctal plug.

References

    1. Allison K., Patel D., Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. 2020;12:e11686. doi: 10.7759/cureus.11686. - DOI - PMC - PubMed
    1. Schuster A.K., Erb C., Hoffmann E.M., Dietlein T., Pfeiffer N. The Diagnosis and Treatment of Glaucoma. Dtsch. Ärzteblatt Int. 2020;117:225. doi: 10.3238/arztebl.2020.0225. - DOI - PMC - PubMed
    1. Weinreb R.N., Aung T., Medeiros F.A. The Pathophysiology and Treatment of Glaucoma: A Review. JAMA. 2014;311:1901. doi: 10.1001/jama.2014.3192. - DOI - PMC - PubMed
    1. Newman-Casey P.A., Robin A.L., Blachley T., Farris K., Heisler M., Resnicow K., Lee P.P. The Most Common Barriers to Glaucoma Medication Adherence. Ophthalmology. 2015;122:1308–1316. doi: 10.1016/j.ophtha.2015.03.026. - DOI - PMC - PubMed
    1. Olthoff C., Schouten J., Vandeborne B., Webers C. Noncompliance with Ocular Hypotensive Treatment in Patients with Glaucoma or Ocular HypertensionAn Evidence-Based Review. Ophthalmology. 2005;112:953–961.E7. doi: 10.1016/j.ophtha.2004.12.035. - DOI - PubMed

LinkOut - more resources